RGEN

Company Overview — What Does REPLIGEN CORP Do?

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. REPLIGEN CORP (RGEN) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Tony J. Hunt and employs approximately 2,020 people, headquartered in Waltham, Massachusetts. With a market capitalization of $6.7B, RGEN is one of the notable companies in the Healthcare sector.

REPLIGEN CORP (RGEN) Stock Rating — Reduce (April 2026)

As of April 2026, REPLIGEN CORP receives a Reduce rating with a composite score of 39.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RGEN ranks #2,690 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, REPLIGEN CORP ranks #363 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RGEN Stock Price and 52-Week Range

REPLIGEN CORP (RGEN) currently trades at $120.10. The stock gained $0.32 (0.3%) in the most recent trading session. The 52-week high for RGEN is $175.77, which means the stock is currently trading -31.7% from its annual peak. The 52-week low is $102.97, putting the stock 16.6% above its annual trough. Recent trading volume was 541K shares, suggesting relatively thin trading activity.

Is RGEN Overvalued or Undervalued? — Valuation Analysis

REPLIGEN CORP (RGEN) carries a value factor score of 43/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 186.03x, compared to the Healthcare sector average of 23.63x — a premium of 687%. The price-to-book ratio stands at 3.09x, versus the sector average of 2.75x. The price-to-sales ratio is 9.35x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, RGEN trades at 66.51x EV/EBITDA, versus 6.34x for the sector.

Overall, RGEN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

REPLIGEN CORP Profitability — ROE, Margins, and Quality Score

REPLIGEN CORP (RGEN) earns a quality factor score of 46/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 1.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 1.2% versus the sector average of -33.1%.

On a margin basis, REPLIGEN CORP reports gross margins of 51.7%, compared to 71.5% for the sector. The operating margin is 3.8% (sector: -66.1%). Net profit margin stands at 4.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 22.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RGEN Debt, Balance Sheet, and Financial Health

REPLIGEN CORP has a debt-to-equity ratio of 26.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.37x, indicating strong short-term liquidity. Total debt on the balance sheet is $542M. Cash and equivalents stand at $749M.

RGEN has a beta of 1.48, meaning it is more volatile than the broader market — a $10,000 investment in RGEN would be expected to move 47.9% more than the S&P 500 on any given day. The stability factor score for REPLIGEN CORP is 49/100, reflecting average volatility within the normal range for its sector.

REPLIGEN CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, REPLIGEN CORP reported revenue of $695M and earnings per share (EPS) of $0.87. Net income for the quarter was $35M. Gross margin was 51.7%. Operating income came in at $29M.

In FY 2025, REPLIGEN CORP reported revenue of $738M and earnings per share (EPS) of $0.87. Net income for the quarter was $49M. Gross margin was 52.3%. Revenue grew 16.4% year-over-year compared to FY 2024. Operating income came in at $55M.

In Q3 2025, REPLIGEN CORP reported revenue of $189M and earnings per share (EPS) of $0.27. Net income for the quarter was $15M. Gross margin was 53.2%. Revenue grew 21.9% year-over-year compared to Q3 2024. Operating income came in at $17M.

In Q2 2025, REPLIGEN CORP reported revenue of $182M and earnings per share (EPS) of $0.26. Net income for the quarter was $15M. Gross margin was 50.0%. Revenue grew 18.4% year-over-year compared to Q2 2024. Operating income came in at $14M.

Over the past 8 quarters, REPLIGEN CORP has demonstrated a growth trajectory, with revenue expanding from $154M to $695M. Investors analyzing RGEN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RGEN Dividend Yield and Income Analysis

REPLIGEN CORP (RGEN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RGEN Momentum and Technical Analysis Profile

REPLIGEN CORP (RGEN) has a momentum factor score of 30/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

RGEN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, REPLIGEN CORP (RGEN) ranks #363 out of 838 stocks based on the Blank Capital composite score. This places RGEN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RGEN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RGEN vs S&P 500 (SPY) comparison to assess how REPLIGEN CORP stacks up against the broader market across all factor dimensions.

RGEN Next Earnings Date

No upcoming earnings date has been announced for REPLIGEN CORP (RGEN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RGEN? — Investment Thesis Summary

The quantitative profile for REPLIGEN CORP suggests caution. Momentum is weak at 30/100, a headwind for near-term performance.

In summary, REPLIGEN CORP (RGEN) earns a Reduce rating with a composite score of 39.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RGEN stock.

Related Resources for RGEN Investors

Explore more research and tools: RGEN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RGEN head-to-head with peers: RGEN vs AZN, RGEN vs SLGL, RGEN vs VMD.